Irreversible metronidazole encephalopathy in an elderly woman with primary biliary cholangitis

Yuki Onuma1, Masayuki Oki2, Masamichi Komatsu1

  • 1Division of General Internal Medicine Department of Medicine Tokai University Oiso Hospital Isehara Kanagawa Japan.

Insights

Metronidazole (MNZ) can cause irreversible neurological damage, known as MNZ-induced encephalopathy, even though it is usually reversible. Careful medication use is crucial, especially for patients needing high doses or those with liver issues.

Area of Science:

  • Neurology
  • Toxicology
  • Gastroenterology

Background:

  • Primary biliary cholangitis (PBC) is a chronic liver disease.
  • Metronidazole (MNZ) is an antibiotic commonly used for various infections.

Observation:

  • An 82-year-old woman with PBC developed an irreversible neurological disorder.
  • The condition was diagnosed as metronidazole-induced encephalopathy.

Findings:

  • Metronidazole-induced encephalopathy, while typically reversible, can lead to severe, permanent neurological deficits in rare instances.
  • This case highlights the potential for serious sequelae, including fatality, from MNZ-induced encephalopathy.

Implications:

  • Judicious use of metronidazole is essential, particularly in elderly patients or those with compromised liver function.
  • Long-term or high-dose metronidazole therapy requires careful monitoring to prevent neurotoxicity.
  • This case underscores the importance of considering drug-induced neurological disorders in differential diagnoses, especially in vulnerable patient populations.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
232
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
619
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
282
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
281